Awards & Advancement

Zymeworks completes $8.1 million financing round

Friday, September 23, 2011 11:26 AM

Zymeworks, a privately held biotherapeutics company, has completed a financing round totaling $8.1 million. The financing consists of a follow-on round of institutional investment by CTI Life Sciences Fund, as well as a new investment by Advanced Biotechnologies Venture Fund and investments by several existing private shareholders. Zymeworks will use the proceeds to advance its Azymetric and AlbuCORE platforms, as well as the development of its protein therapeutics pipeline in the areas of cancer, autoimmunity and inflammatory diseases.

More... »

Celniker and Schor join Eleven Biotherapeutics

Friday, September 23, 2011 11:09 AM

Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing protein-based therapeutics, has named Abbie Celniker, Ph.D., chief executive officer.

More... »

Aldredge joins Expression Analysis

Wednesday, September 21, 2011 10:57 AM

Expression Analysis, a provider of genetic and genomic testing and analysis for the pharmaceutical and biotechnology industries, has named Tyler Aldredge vice president of laboratory operations.

More... »

StudyManager awarded Army contract for mild TBI study

Tuesday, September 20, 2011 02:46 PM

StudyManager, a leading provider of clinical trial management software (CTMS) and electronic data capture (EDC) solutions, has reported that BalanceSense awarded StudyManager an eight-site, phase II Army contract to implement Evolve CTMS and EDC.

More... »

Tokai Pharmaceuticals raises $23 million in funding

Tuesday, September 20, 2011 01:45 PM

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $23 million in a Series D3 financing. The proceeds will be used to support the ongoing clinical development of galeterone (TOK-001), the company's lead drug candidate, which has completed an initial proof-of-concept phase 1 clinical trial for the treatment of patients with castration resistant prostate cancer (CRPC). The financing round included both current investors, Novartis Venture Fund and Apple Tree Partners.

More... »

PPD names Hill CEO

Tuesday, September 20, 2011 10:14 AM

CRO PPD, which has been the subject of takeover speculation since July, has named Raymond Hill its new chief executive officer, filling a position that was vacant since mid-May, according to a PharmaTimes report.

More... »

KYTHERA raises $37.4 million in Series D financing

Monday, September 19, 2011 01:17 PM

KYTHERA Biopharmaceuticals has closed a $37.4M Series D financing round. The round featured significant new investments as well as participation from all existing institutional investors. Proceeds from this financing are slated to be used for conducting US phase III trials for KYTHERA's lead product, ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.

More... »

Madaus joins Quanterix as CEO

Monday, September 19, 2011 01:06 PM

Quanterix has named Martin D. Madaus, Ph.D. chief executive officer. Madaus, who also retains his position as chairman, brings more than 20 years of experience in the diagnostics and life science industries, most recently serving as president, chairman and CEO of Millipore, acquired by Merck. 

More... »

Holmlund joins Aspire IRB

Thursday, September 15, 2011 10:17 AM

Aspire IRB has named Jon Holmlund, MD, medical director. As medical director, Holmlund is responsible for providing medical and scientific expertise and leadership to ensure the protection of people participating in human research studies reviewed and overseen by Aspire. 

More... »

Roche names head of small molecules research

Wednesday, September 14, 2011 11:44 AM

Roche has named Rainer Metternich, PhD, head of small molecules research (SMR), effective immediately. He takes over from Klaus Strein, who will retire from Roche.

More... »